[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100606135":3},{"organization":4,"armGroups":7,"interventions":30,"overallOfficials":11,"centralContacts":47,"locations":53,"responsibleParty":68,"collaborators":11,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":11,"eligibilityCriteria":75,"healthyVolunteers":72,"sex":76,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":11,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":11,"overallStatus":56,"whyStopped":11,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Shenyang Sunshine Pharmaceutical Co., LTD.","INDUSTRY",[8,14,17,21,25],{"label":9,"type":10,"description":11,"interventionNames":12},"dose level 1 of SSGJ-706 monotherapy","EXPERIMENTAL",null,[13],"Drug: SSGJ-706",{"label":15,"type":10,"description":11,"interventionNames":16},"dose level 2 of SSGJ-706 monotherapy",[13],{"label":18,"type":10,"description":11,"interventionNames":19},"dose level 1 of SSGJ-706 combined with chemotherapy",[13,20],"Drug: pemetrexed \u002Fcarboplatin",{"label":22,"type":10,"description":11,"interventionNames":23},"dose level 2 of SSGJ-706 combined with chemotherapy",[13,24],"Drug: Carboplatin\u002FPaclitaxel",{"label":26,"type":27,"description":11,"interventionNames":28},"PD-1\u002FL1 combined with chemotherapy","ACTIVE_COMPARATOR",[29],"Drug: PD-1 Inhibitor + Chemotherapy",[31,36,40,43],{"type":32,"name":33,"description":34,"armGroupLabels":35,"otherNames":11},"DRUG","SSGJ-706","PD-1\u002FPD-L1 bispecific antibody",[18,9,22,15],{"type":32,"name":37,"description":38,"armGroupLabels":39,"otherNames":11},"pemetrexed \u002Fcarboplatin","chemotherapy",[18],{"type":32,"name":41,"description":38,"armGroupLabels":42,"otherNames":11},"Carboplatin\u002FPaclitaxel",[22],{"type":32,"name":44,"description":45,"armGroupLabels":46,"otherNames":11},"PD-1 Inhibitor + Chemotherapy","control group",[26],[48],{"name":49,"role":50,"phone":51,"phoneExt":11,"email":52},"Shengxiang Ren","CONTACT","13816756732","harry_ren@126.com",[54],{"facility":55,"status":56,"city":57,"state":11,"zip":11,"country":58,"countryCode":59,"cosmosGeoPoint":60,"geoPoint":65,"contacts":66},"Institute of The Shanghai Pulmonary Hospital","RECRUITING","Shanghai","China","CN",{"type":61,"coordinates":62},"Point",[63,64],121.45806,31.22222,{"lat":64,"lon":63},[67],{"name":49,"role":50,"phone":51,"phoneExt":11,"email":52},{"type":69,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100606135","phase-2-a-phase-ii-study-of-ssgj-706-monotherapy-and-combination-therapy-in-advanced-non-small-cell-lung-cancernsclc-patients-100606135",false,"NCT07171606","A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients","Inclusion Criteria:\n\n1. Males and\u002For females over age 18\n2. Histologically and\u002For cytologically documented local advanced or metastatic NSCLC .\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n4. Expected survival \\>=3 months.\n5. Signed informed consent form.\n\nExclusion Criteria:\n\n1. Known uncontrolled or symptomatic central nervous system metastatic disease.\n2. Adverse events (with exception of alopecia and fatigue) from any prior anticancer therapy of grade \\>1 (National Cancer Institute Common terminology Criteria \\[NCI CTCAE\\] v.5.0).\n3. Inadequate organ or bone marrow function.\n4. Pregnant or breast-feeding woman.\n5. Known allergies, hypersensitivity, or intolerance to SSGJ-706\n\nThe above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.","ALL","18 Years","75 Years",{"count":80,"type":81},240,"ESTIMATED","INTERVENTIONAL",[84],"PHASE2","This study includes two parts, part 1 is SSGJ-706 monotherapy therapy for advanced NSCLC and part 2 is SSGJ-706 combination therapy for advanced NSCLC",[87],"First-line Advanced NSCLC Patients","2025-12-10",{"date":90,"type":91},"2025-12-18","ACTUAL",{"date":93,"type":91},"2025-10-24",{"date":95,"type":81},"2027-08-31",{"name":5,"class":6},1]